Flag of the European Union EU Clinical Trials Register Help

Clinical trials for NF

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: NF. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-003855-65 Sponsor Protocol Number: 090701 Start Date*: 2009-09-21
    Sponsor Name:Baxter Innovations GmbH
    Full Title: FEIBA NF: A prospective, open-label, randomized, parallel study to evaluate efficacy and safety of prophylactic versus on-demand treatment in subjects with hemophilia A or B and a high titer inhibitor
    Medical condition: Hemophilia A or B and a high titer inhibitor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056492 Haemophilia A with anti factor VIII LLT
    9.1 10056494 Haemophilia B with anti factor IX LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-015242-30 Sponsor Protocol Number: 2009-001 Start Date*: 2009-11-05
    Sponsor Name:The Walton Centre for Neurology and Neurosurgery NHS Trust
    Full Title: An open study to compare the efficacy of immunoglobulin administered subcutaneoulsy (SCIG) with current best practice in patients with Complex Regional Pain Syndrome (CRPS)
    Medical condition: Complex Regional Pain Syndrome (CRPS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001361-28 Sponsor Protocol Number: GO29365 Start Date*: 2015-10-07
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Phase Ib/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relapsed or ref...
    Medical condition: Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    20.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    20.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Completed) FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001846-15 Sponsor Protocol Number: CSUC-01/06 Start Date*: 2006-12-06
    Sponsor Name:InDex Pharmaceuticals AB
    Full Title: A placebo-controlled, randomised, double-blind, single dose proof of concept study of Kappaproct, in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degree
    Medical condition: Active ulcerative colitis in steroid refractory or steroid dependent patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001789-16 Sponsor Protocol Number: PenCTU/2011/CTIMP-005 Start Date*: 2011-08-26
    Sponsor Name:Plymouth Hospital NHS Trust
    Full Title: Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas
    Medical condition: Neurofibromatosis, type 2 (acoustic neurofibromatosis)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10029271 Neurofibromatosis, type 2 (acoustic neurofibromatosis) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002196-34 Sponsor Protocol Number: Neo.Lu.Pa.NET Start Date*: 2019-11-07
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET)
    Medical condition: Resectable pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004835-26 Sponsor Protocol Number: D169AL00005 Start Date*: 2021-05-24
    Sponsor Name:IRCCS-A.O.U. SAN MARTINO-IST
    Full Title: Single-center, randomized, controlled study to evaluate the effects of a six-month treatment with renal glucose transport inhibitor (SGLT2i) drugs on markers of senescence, inflammation and tubuloi...
    Medical condition: Chronic Kidney Deseas
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10050441 Chronic renal insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003160-19 Sponsor Protocol Number: ASL608LIOM01 Start Date*: 2008-09-07
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETR...
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001167 Adenocarcinoma of colon LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002228-42 Sponsor Protocol Number: P101202 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10029268 Neurofibromatosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002520-16 Sponsor Protocol Number: 626 Start Date*: 2007-07-06
    Sponsor Name:Universitätsklinik für klinische Pharmakologie, Medizinische Universität Wien
    Full Title: The effects of post-conditioning and administration of Vitamin C on intramuscular high energy phosphate levels
    Medical condition: ischemia reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023034 Ischemia peripheral LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005770-26 Sponsor Protocol Number: KRONF2 Start Date*: 2023-10-20
    Sponsor Name:Medical University of Warsaw
    Full Title: Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded f...
    Medical condition: Neurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000523 Acoustic neuroma PT
    27.0 10010331 - Congenital, familial and genetic disorders 10029271 Neurofibromatosis, type 2 (acoustic neurofibromatosis) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003111-31 Sponsor Protocol Number: 2007-1-18-20-6 Start Date*: 2008-07-21
    Sponsor Name:Charité - Universitaetsmedizin Berlin
    Full Title: Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative ...
    Medical condition: Post-operative immunological stimulation in severe immune suppression. The study population is made up of adult, which are able to give their inform consent by their own. The patients are undergoin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002231-27 Sponsor Protocol Number: LOB-LEV-2005-02 Start Date*: 2006-01-16
    Sponsor Name:Clínica del Dr. Lobatón
    Full Title: Estudio prospectivo, in vivo, aleatorizado, controlado, abierto, de fase IV, en grupos paralelos para medir el efecto de los antihistamínicos (levocetirizina 5 mg/día y ebastina 20 mg/día, vía oral...
    Medical condition: Rinitis alérgica estacional
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039776 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001933-16 Sponsor Protocol Number: 26866138PCR2002 Start Date*: 2007-03-13
    Sponsor Name:Christos N. Papandreou
    Full Title: "A Phase II, Open-Label study of Velcade(Bortezomib)for patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy"
    Medical condition: Treatment of patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy.
    Disease:
    Population Age: Gender: Male
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004626-17 Sponsor Protocol Number: 1101/08 Start Date*: 2009-03-23
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Anti-inflammatory and Anti-platelet effect of Clopidogrel and Aspirin vs Aspirin alone in Symptomatic Polyvascular disease and in patients with multiple recurrent cardiovascular events.
    Medical condition: Polyvascular disease and in patients with multiple recurrent cardiovascular events.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10032377 Other peripheral vascular disease LLT
    9.1 10028600 Myocardial ischaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004284-27 Sponsor Protocol Number: CA043-001 Start Date*: 2022-01-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
    Medical condition: Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC)...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000190-28 Sponsor Protocol Number: IMD-10412002-1 Start Date*: 2007-03-22
    Sponsor Name:Institute of Medicinal Molecular Design Inc
    Full Title: A Single Centre, Double-blind, Randomised Study To Investigate a Single Oral Dose of IMD-1041 in A Nasal Allergen Challenge (NAC) Model
    Medical condition: It is intended to investigate the potential therapeutic benefit of IKKβ inhibition in man by oral dosing of IMD-1041 in a Nasal Alllergen Challenge.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10053467 Antiinflammatory therapy PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019759-23 Sponsor Protocol Number: PET-CT140410 Start Date*: 2011-01-12
    Sponsor Name:Guys' and St. Thomas' NHS Foundation Trust
    Full Title: Evaluation of [11C]-methionine positron emission computerised tomography (PET CT) in diagnosing neurofibromatosis 1(NF1) - malignant peripheral nerve sheath tumours (MPNST)
    Medical condition: The diagnosis of malignant peripheral nerve sheath tumours in patients with neurofibromatosis 1
    Disease: Version SOC Term Classification Code Term Level
    12 10029268 Neurofibromatosis 1 associated malignant peripheral nerve sheath tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019937-85 Sponsor Protocol Number: dmestatina Start Date*: 2010-09-16
    Sponsor Name:Dr. Luis Serra Majem
    Full Title: Dieta Mediterránea, Ejercicio y Estatinas en el Tratamiento de la Dislipemia
    Medical condition: Dislipidemia
    Disease: Version SOC Term Classification Code Term Level
    11 10058108 Dislipidemia PT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003297-13 Sponsor Protocol Number: D5892N00005 Start Date*: 2005-12-01
    Sponsor Name:Imperial College
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group study to investigate the effect of Symbicort® and Pulmicort® on HAT and HDAC expression and activity in induced sputum cells obtained ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 19 13:11:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA